Renal denervation as option for patients with hypertension despite medications

Media formats available:

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Prof. Peter Libby, MD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
A call to solve the controversy on omega-3FAs trials
A call to solve the controversy on omega-3FAs trials
ACC.21
A call to solve the controversy on omega-3FAs trials
- Prof. Eileen Handberg, PhD
No definite difference for primary endpoint but proven safety with ARNI in MI patients
No definite difference for primary endpoint but proven safety with ARNI in MI patients
ACC.21
No definite difference for primary endpoint but proven safety with ARNI in MI patients
- Prof. Marc Pfeffer, MD, PhD

PACE-CME